83 FR 8658 - Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

DEPARTMENT OF DEFENSE

Federal Register Volume 83, Issue 40 (February 28, 2018)

Page Range		8658-8658
FR Document		2018-04066

The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.

Federal Register, Volume 83 Issue 40 (Wednesday, February 28, 2018)

[Federal Register Volume 83, Number 40 (Wednesday, February 28, 2018)]
[Notices]
[Page 8658]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-04066]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES: Open to the public Thursday, April 5, 2018 from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, U.S. Navy, 703-
681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: http://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found 
on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    The Panel will review and comment on recommendations made to the 
Director of the Defense Health Agency, by the Pharmacy and Therapeutics 
Committee, regarding the Uniform Formulary.
    Purpose of the Meeting: The Department of Defense is publishing 
this notice to announce a Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel).
    Agenda: Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item). a. Diabetes Non-Insulin: Glucagon-Like Peptide 1 Receptor 
Agonists Subclass. b. Osteoporosis Drugs: Parathyroid Hormone (PTH) 
Analog Subclass. c. Anti-Inflammatory Immunomodulatory Ophthalmic 
Agents--Ophthalmic Immunomodulatory Agents Subclass. d. 
Corticosteroids-Immune Modulators--Adrenocorticotropic Hormones 
Subclass. 4. Newly Approved Drugs Review. 5. Pertinent Utilization 
Management Issues. 6. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel about its mission and/or the agenda to be 
addressed in this public meeting. Written statements should be 
submitted to the Panel's Designated Federal Officer (DFO). The DFO's 
contact information can be obtained previously in this announcement. 
Written comments or statements must be received by the committee DFO at 
least five (5) business days prior to the meeting so that they may be 
made available to the Panel for its consideration prior to the meeting. 
The DFO will review all submitted written statements and provide copies 
to all the committee members.

    Dated: February 23, 2018.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2018-04066 Filed 2-27-18; 8:45 am]
BILLING CODE 5001-06-P

8658 Federal Register / Vol. 83, No. 40 / Wednesday, February 28, 2018 / Notices

any given form identified by docket DEPARTMENT OF DEFENSE Agents—Ophthalmic
number, form number, and title. Immunomodulatory Agents Subclass. d.
Uniform Formulary Beneficiary Corticosteroids-Immune Modulators—
FOR FURTHER INFORMATION CONTACT: To Advisory Panel; Notice of Federal Adrenocorticotropic Hormones
request more information on this Advisory Committee Meeting Subclass. 4. Newly Approved Drugs
proposed information collection or to Review. 5. Pertinent Utilization
obtain a copy of the proposal and AGENCY: Under Secretary of Defense for
Management Issues. 6. Panel
associated collection instruments, Personnel and Readiness, Department of
Discussions and Vote.
please write to the to the Department of Defense. Meeting Accessibility: Pursuant to 5
the Army, Institute for Water Resources, ACTION: Notice of Federal Advisory U.S.C. 552b, as amended, and 41 Code
Corps of Engineers Waterborne Committee meeting. of Federal Regulations (CFR) 102–3.140
Commerce Statistics Center, P.O. Box through 102–3.165, and the availability
SUMMARY: The Department of Defense
61280, ATTN: Christopher (Dale) of space, this meeting is open to the
(DoD) is publishing this notice to
Brown, New Orleans, LA 70161–1280, public. Seating is limited and will be
announce that the following Federal provided only to the first 220 people
or call Department of the Army Reports Advisory Committee meeting of the
Clearance Officer at (703) 428–6440. signing-in. All persons must sign-in
Uniform Formulary Beneficiary legibly.
SUPPLEMENTARY INFORMATION: Advisory Panel will take place. Written Statements: Pursuant to 41
Title; Associated Form; and OMB DATES: Open to the public Thursday, CFR 102–3.140, the public or interested
Number: Service Members Transitioning April 5, 2018 from 9:00 a.m. to 12:00 organizations may submit written
from Active Duty to Veterans Status; p.m. statements to the membership of the
OMB Control Number 0702–XXXX. ADDRESSES: The address of the open Panel about its mission and/or the
meeting is the Naval Heritage Center agenda to be addressed in this public
Needs and Uses: This study, meeting. Written statements should be
Theater, 701 Pennsylvania Avenue NW,
exploratory in nature, is designed to submitted to the Panel’s Designated
Washington, DC 20004.
capture baseline data prior to transition Federal Officer (DFO). The DFO’s
and at three subsequent data points after FOR FURTHER INFORMATION CONTACT:
contact information can be obtained
the transition out of service. The CAPT Edward Norton, U.S. Navy, 703–
previously in this announcement.
purpose of data capture before, during, 681–2890 (Voice), None (Facsimile),
Written comments or statements must
dha.ncr.health-it.mbx.baprequests@
and after transition is to allow the be received by the committee DFO at
mail.mil (Email). Mailing address is
researchers to monitor how transition least five (5) business days prior to the
7700 Arlington Boulevard, Suite 5101,
stressors change over time and what meeting so that they may be made
Falls Church, VA 22042–5101. Website:
factors might influence their course. available to the Panel for its
http://www.health.mil/About-MHS/
This information will be enormously consideration prior to the meeting. The
Other-MHS-Organizations/Beneficiary-
useful in attempts to design and DFO will review all submitted written
Advisory-Panel. The most up-to-date
implement interventions that might statements and provide copies to all the
changes to the meeting agenda can be
target these stressors. committee members.
found on the website.
Participants will be recruited during a SUPPLEMENTARY INFORMATION: This
Dated: February 23, 2018.
set nine month window in which meeting is being held under the Aaron Siegel,
Service Members have self-identified as provisions of the Federal Advisory Alternate OSD Federal Register Liaison
transitioning out of the service within Committee Act (FACA) of 1972 (5 Officer, Department of Defense.
the six months. Participation in the U.S.C., Appendix, as amended), the [FR Doc. 2018–04066 Filed 2–27–18; 8:45 am]
study is voluntary and participants will Government in the Sunshine Act of BILLING CODE 5001–06–P

be consented twice, once at baseline 1976 (5 U.S.C. 552b, as amended), and
(time point 1) while the Service Member 41 CFR 102–3.140 and 102–3.150.
The Panel will review and comment DEPARTMENT OF DEFENSE
is still active duty and then again at time
point 2 as civilians. This burden on recommendations made to the
Office of the Secretary
information only accounts for the public Director of the Defense Health Agency,
being affected. by the Pharmacy and Therapeutics [Docket ID: DOD–2018–OS–0006]
Committee, regarding the Uniform
Affected Public: Individuals and Formulary. Proposed Collection; Comment
Households. Purpose of the Meeting: The Request
Annual Burden Hours: 350 Hours. Department of Defense is publishing AGENCY: Defense Finance and
Number of Respondents: 600. this notice to announce a Federal Accounting Service, DoD.
Advisory Committee meeting of the ACTION: Information collection notice.
Responses per Respondent: 1. Uniform Formulary Beneficiary
Annual Responses: 600. Advisory Panel (hereafter referred to as SUMMARY: In compliance with the
Average Burden per Response: 35 the Panel). Paperwork Reduction Act of 1995, the
minutes. Agenda: Meeting Agenda: 1. Sign-In. Defense Finance and Accounting
2. Welcome and Opening Remarks. 3. Service announces a proposed public
Frequency: Annually. Scheduled Therapeutic Class Reviews information collection and seeks public
sradovich on DSK3GMQ082PROD with NOTICES

Dated: February 23, 2018. (Comments will follow each agenda comment on the provisions thereof.
Aaron Siegel, item). a. Diabetes Non-Insulin: Comments are invited on: Whether the
Glucagon-Like Peptide 1 Receptor proposed collection of information is
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
Agonists Subclass. b. Osteoporosis necessary for the proper performance of
Drugs: Parathyroid Hormone (PTH) the functions of the agency, including
[FR Doc. 2018–04059 Filed 2–27–18; 8:45 am]
Analog Subclass. c. Anti-Inflammatory whether the information shall have
BILLING CODE 5001–06–P
Immunomodulatory Ophthalmic practical utility; the accuracy of the

VerDate Sep<11>2014 17:25 Feb 27, 2018 Jkt 244001 PO 00000 Frm 00010 Fmt 4703 Sfmt 4703 E:\FR\FM\28FEN1.SGM 28FEN1

Document Created: 2018-02-28 03:19:52
Document Modified: 2018-02-28 03:19:52

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice of Federal Advisory Committee meeting.
Dates		Open to the public Thursday, April 5, 2018 from 9:00 a.m. to 12:00 p.m.
Contact		CAPT Edward Norton, U.S. Navy, 703- 681-2890 (Voice), None (Facsimile), dha.ncr.health-
FR Citation		83 FR 8658